Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies  - Summary - MDSpire

Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies 

Eugene M. & Christine E. Lynn Cancer Institute has treated its first patient with tarlatamab, marking an important milestone in the expansion of advanced cancer therapies available to patients in Palm Beach County and the surrounding region.

  • May 7, 2026

  • 3 min

Share

Objective:

To highlight the treatment of the first patient with tarlatamab at Lynn Cancer Institute.

Key Findings:
  • Tarlatamab is administered as part of a coordinated effort involving oncology, nursing, laboratory, pharmacy, emergency medicine, critical care, and caregiver support.
  • The treatment requires a coordinated cancer center infrastructure for effective delivery.
Interpretation:

Limitations:
  • The complexity of tarlatamab treatment necessitates a well-coordinated team effort, which may not be available in all healthcare settings.
Conclusion:

The treatment of the first patient with tarlatamab has occurred at Lynn Cancer Institute.

Original Source(s)

Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies 

  • May 7, 2026

Related Content

New AI-Enabled Technology Supports Radiology Follow-Up Throughout Baptist Health

Baptist Health Herbert Wertheim Cancer Institute has launched Eon, an AI-enabled software platform that analyzes radiology reports and helps identify and prioritize incidental findings for clinical review, in an effort to support timely, coordinated patient care.

  • by

  • July 1, 2026

  • 2 min
AI Framework Helps Identify New CAR T Target

A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models

  • July 6, 2026

  • 3 min
2026 AACR Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min